Purchases are not available yet. You can browse the site and sign in.
LSD Microdosing Sleep Study Explained · Microdosing College
Science
LSD Microdosing and Sleep: What the Wearable Sleep Study Found
By Microdosing College Editorial·Last updated August 23, 2026·7 min read
The LSD microdosing sleep study at a glance
The phrase lsd microdosing sleep study refers to a specific placebo-controlled trial published in 2024 by Allen and colleagues, available open-access via PubMed Central (Allen et al., 2024, PMC). It is one of the few rigorous, controlled investigations of what microdose LSD does to objective sleep metrics — and its headline result is counterintuitive enough to deserve a careful read.
Participants wore consumer sleep-tracking devices across multiple dosing sessions. The key finding: 10 micrograms of LSD did not meaningfully disrupt sleep on the dose night itself, but on the following night it added approximately 24 minutes of total sleep time and roughly 8 minutes of REM sleep compared with placebo. In other words, the effect was delayed by roughly 24 hours.
For anyone trying to design a sustainable microdosing protocol, that delay is the most practically important detail in the paper.
What the study actually did
The Allen et al. study used a within-subject, placebo-controlled design — each participant served as their own control across conditions, which is a methodological strength because it removes the between-person variability that plagues much microdosing research. The dose chosen, 10 µg of LSD, sits at the lower end of what most microdosers self-report using; a typical self-administered microdose ranges from 5–20 µg, so 10 µg is a reasonable mid-range anchor.
Sleep was measured with wearable devices rather than in-lab polysomnography. That is a limitation: consumer wearables cannot match a clinical EEG for accuracy, especially in distinguishing lighter sleep stages. The authors acknowledge this. However, the wearable approach allowed participants to sleep in their own beds in ecologically natural conditions, and it enabled a study size that would be prohibitively expensive using full polysomnography. Real-world data with acknowledged noise is often more practically useful than pristine lab data that does not generalise.
The primary outcomes were total sleep time, REM sleep, and sleep efficiency. The 24-minute total sleep increase and ~8-minute REM increase were statistically significant against placebo.
Why the effect appears the next night
LSD has a long half-life relative to psilocybin. Where psilocin (the active form of psilocybin) is largely cleared within a few hours — its elimination half-life is roughly 1.4–2 hours (Holze et al., 2023, Clinical Pharmacology & Therapeutics) — LSD at a full dose can last 8–12 hours, and even at 10 µg a pharmacological signal may persist into the evening. The activation of serotonin 5-HT2A receptors and catecholaminergic pathways that gives LSD its stimulating character at recreational doses may be enough, even at low doses, to shift the brain's sleep pressure or circadian signalling.
One plausible mechanism is REM rebound. If LSD partially suppresses REM on the dose night — even subclinically, in a way that doesn't feel like disrupted sleep — the brain may compensate the following night with a modest increase in REM. The magnitude found in Allen et al. (~8 minutes) is not large, but it is consistent in direction with what is known about serotonergic drugs and REM sleep. Serotonin generally suppresses REM, and as serotonergic tone returns to baseline after LSD clearance, a compensatory rebound is plausible.
This also matters for understanding the physiological effects of LSD microdoses more broadly: the Bershad et al. (2019) lab study documented dose-dependent cardiovascular and subjective effects at doses as low as 6.5–25 µg, which establishes that 10 µg is not pharmacologically inert.
What this means for protocol timing
The next-night sleep benefit has a direct implication for when you dose within a cycle. If you follow the classic Fadiman protocol (dose on day 1, rest on days 2 and 3), the sleep bonus naturally falls on your first rest day — which most people regard as a positive. The dose day itself is not the night you will feel well-rested; the following night may be.
For a deeper look at how this interacts with protocol design, see our article on microdosing and sleep protocol timing. The short practical takeaways from the Allen et al. findings are:
Dose earlier in the day — LSD's stimulating properties are amplified if it is taken in the afternoon; morning dosing allows maximum clearance before bedtime.
Do not interpret a slightly restless dose night as a sign something went wrong — the recovery may come the next night.
Track it — because the effect size is modest (24 minutes is meaningful but not dramatic), subjective impression without a sleep tracker will likely miss it entirely. Wearables have limitations, but they are far more reliable than pure recall.
For context on how sleep quality relates to microdosing more broadly, including psilocybin, see our overview on microdosing and sleep quality.
Interpreting a single study: what we don't yet know
The Allen et al. result is genuinely interesting, but it is one study with a specific population (healthy adults, presumably without sleep disorders), a specific dose (10 µg), and a specific measurement tool (wearables). Several open questions remain:
Does the effect scale with dose? The study did not test multiple dose levels, so it is unknown whether 5 µg or 20 µg produces a different sleep profile. The dose-dependent physiological effects documented by Bershad et al. at higher microdose ranges suggest that dose matters, but sleep data at other levels are not yet published.
Does it persist across a multi-week protocol? A single acute measure tells us what happens on one cycle. Whether the next-night sleep benefit holds over weeks — or whether tolerance or adaptation erodes it — has not been tested.
Is the wearable signal reliable enough? Consumer devices vary in their sleep-staging algorithms. The authors' acknowledgement of this limitation is appropriate; readers should treat the specific numbers (24 min, 8 min REM) as order-of-magnitude estimates rather than precise measurements.
What about people with existing sleep disorders? Studies recruiting healthy volunteers do not generalise automatically to people with insomnia, sleep apnoea, or other conditions. If sleep is already disrupted, the dynamics may be quite different. Use the self-screener before considering any microdosing practice if you have a health condition.
It is also worth placing this finding in the broader context of microdosing evidence quality: one controlled trial with wearables is a meaningful step forward from pure self-report, but it is not a definitive answer. The self-selection bias in naturalistic microdosing research that affects survey studies does not disappear entirely even in controlled designs — participant motivation and expectation still shape outcomes in subtle ways, particularly for subjective sleep quality ratings.
The bottom line
The Allen et al. (2024) wearable sleep study is a well-designed, placebo-controlled data point showing that a 10 µg LSD microdose can add meaningful sleep time — but the window is the night after dosing, not the dose night itself. The magnitude is modest: roughly 24 minutes of total sleep and 8 minutes of REM. That is not transformative, but it is statistically significant and practically relevant for protocol planning.
For those who microdose LSD and have noticed they sleep better on their rest days, this study offers a plausible physiological explanation. For those designing protocols, it reinforces morning dosing as the sensible default. As with all microdosing research, a single study warrants interest, not certainty — and nothing here constitutes medical advice or a recommendation to use any controlled substance. If you are weighing whether microdosing is appropriate for you, start with the research library and the self-screener at /screener.
Frequently asked
What did the LSD microdosing sleep study find?+
Allen et al. (2024) found that 10 micrograms of LSD increased total sleep time by approximately 24 minutes and REM sleep by about 8 minutes compared with placebo — but these effects appeared the night after dosing, not on the dose night itself.
Why does the sleep benefit appear the next night rather than the dose night?+
LSD activates serotonergic pathways that can partially suppress REM and increase arousal on the dose night, even at sub-perceptual doses. As the drug clears, the brain may compensate with a modest REM rebound the following night — a pattern consistent with how serotonergic drugs generally affect sleep architecture.
How reliable are wearable sleep trackers for measuring these effects?+
Consumer wearables cannot match clinical polysomnography for sleep-stage accuracy, particularly in distinguishing lighter NREM stages. Allen et al. acknowledge this limitation. The advantage is ecological validity — participants sleep at home — but the specific numbers (24 min, 8 min REM) should be treated as estimates rather than precise measurements.
Does this mean LSD microdosing improves sleep?+
The study shows a statistically significant next-night increase in sleep time in healthy adults at 10 µg — that is a meaningful finding. However, it is one study with one dose level and a specific population. It does not establish that LSD microdosing is an appropriate or effective intervention for sleep problems, and it does not generalise to people with sleep disorders or other health conditions.
What does the next-night sleep effect mean for dosing schedule?+
It supports dosing in the morning so that any stimulating pharmacological effects from LSD clear before bedtime. On a standard Fadiman protocol (dose day 1, rest days 2–3), the sleep benefit falls naturally on the first rest day, which most people consider positive.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
